Philadelphia
,
US
11 - 13 November 2023
American Heart Association (AHA 2023)
Presentation schedule and materials
Saturday, 11 November 2023
08:30
- 08:42
EST
ORAL PRESENTATION
Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity and Cardiovascular Disease Who Do Not Have Diabetes
A. Michael Lincoff1; Kirstine Brown-Frandsen2; Helen M. Colhoun3; John Deanfield4; Scott S. Emerson5; Sille Esbjerg2; Søren Hardt-Lindberg2; G. Kees Hovingh2,6; Steven E. Kahn7; Robert F. Kushner8; Ildiko Lingvay9; Tugce K. Oral2; Marie M. Michelsen2; Jorge Plutzky10; Christoffer W. Tornøe2; Donna H. Ryan11; for the SELECT Trial Investigators
11:30
EST
Sa3237
POSTER
Recruitment Strategies For a Remote Implementation Study in Risk Management of Cardiovascular and/or Kidney Complications in Diabetes – Insights Into Optimizing Enrollment
Hassan S1; Chang LS1; Colling C2; Chasse J1; Stern G1; Gabovitch D1; Zelle D3; Aronson S3; Figueroa C3; Collins E3; Ruggiero R3; Zacherle E4; Noone J4; Robar C4; Gaziano T1; Plutzky J1; Matta L1; Cannon CP1; Wexler DJ2; Scirica BM1; Blood AJ1
12:00
- 13:15
EST
MDP50
ORAL PRESENTATION
Contemporary Prevalence, Comorbidity Burden, and Treatment of Overweight and Obesity: Insights From the Multicenter Mass General Brigham Healthcare System
John Ostrominski1,3,6; Kelly Olsson7; Austen Smith4,6; Ozan Unlu1,3,6; David Zelle1; Michela Tucci1; Joshua Toliver7; Wojciech Michalak7; Anthony Fabricatore7; Briain O’Hartaigh7; Heather Baer5,6; Caroline Apovian4,6; Christopher Cannon1,3,6; Benjamin Scirica1,3,6; Alexander Blood1,2,3,6
Sunday, 12 November 2023
09:45
- 09:57
EST
23482
ORAL PRESENTATION
Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: A prespecified analysis of the STEP-HFpEF trial
Mikhail N. Kosiborod1; Subodh Verma2; Barry A. Borlaug3; Javed Butler4; Melanie Davies5; G. Kees Hovingh6; Mark Petrie7; Sanjiv J. Shah8; Daniél Vega Møller6; Thomas Jon Jensen6; Søren Rasmussen6; Peter Erlang Marstrand6; Hiroshi Ito9; Morten Schou10; Walter Abhayaratna11; Dalane Kitzman12
11:30
EST
Su3010
POSTER
Prevalence of Atherosclerosis, Heart Failure, and Chronic Kidney Disease Among Patients With Type 2 Diabetes and Management With Diabetes Pharmacotherapy
Cori Rattelman1; Carey A. Robar2; Jigar Rajpura2; Jeff Mohl1
15:30
EST
Su3279
POSTER
Contemporary Practice Patterns and Opportunities to Improve Type 2 Diabetes (T2D) Therapy in Patients at Elevated Cardiovascular (CV) and/or Kidney Risk
Blood AJ1; Chang LS1; Colling C2; Stern GM1; Gabovitch D1; Zelle DJ1; Zacherle E3; Noone J3; Robar C3; Matta L1; Aronson S1; Gaziano T1; Plutzky J1; Cannon CP1; Wexler DJ2; Scirica BM1
15:30
EST
Su3107
POSTER
Predictors of elevated high-sensitivity C-reactive protein in a US population with atherosclerotic cardiovascular disease: results from the National Health and Nutrition Examination Survey
Kausik K Ray1; Mads D Faurby2; Gasper Letnar3; Søren Lophaven3,4; Jimmi Mathisen4; Michael G Nanna5; Simon Bertram Reuter4; Naveed Sattar6; Amir A Mohseni Zonoozi4; Ann Marie Navar7
15:30
EST
Su3033
POSTER
Awareness And Perceptions Towards Inflammatory Risk In Atherosclerotic Cardiovascular Disease: A Multinational Survey Amongst Cardiologists
Marx N1; Komuro I2; Mohseni Zonoozi AA3; Prasad P3; Qian J4; Saraiva JFK5; Shete A6; Catapano AL7
Monday, 13 November 2023
13:30
EST
Mo3084
POSTER
Clinical Burden of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the USA From 2004 to 2022
Kevin M Alexander1; Anne S Ersbøll2; Christiane Lundegaard Haase2; Jimmi Mathisen2; Mathew S Maurer3
Keywords